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Abstract
Background: A central question in cancer biology is what changes cause a healthy cell to form a tumor. Gene
expression data could provide insight into this question, but it is difficult to distinguish between a gene that causes a
change in gene expression from a gene that is affected by this change. Furthermore, the proteins that regulate gene
expression are often themselves not regulated at the transcriptional level. Here we propose a Bayesian modeling
framework we term RegNetB that uses mechanistic information about the gene regulatory network to distinguish
between factors that cause a change in expression and genes that are affected by the change. We test this
framework using human gene expression data describing localized prostate cancer progression.
Results: The top regulatory relationships identified by RegNetB include the regulation of RLN1, RLN2, by PAX4, the
regulation of ACPP (PAP) by JUN, BACH1 and BACH2, and the co-regulation of PGC and GDF15 by MAZ and TAF8.
These target genes are known to participate in tumor progression, but the suggested regulatory roles of PAX4,
BACH1, BACH2, MAZ and TAF8 in the process is new.
Conclusion: Integrating gene expression data and regulatory topologies can aid in identifying potentially causal
mechanisms for observed changes in gene expression.
Background
What changes are responsible for making a tumor a
tumor? If we knew the underlying cause for this change,
then it may be possible to directly address the underlying
dysfunction that causes tumorigenesis. One possible route
to identifying a causal mechanism for tumorigenesis is to
gather a rich body of experimental data describing the
state of many tumors and search for relevant signatures.
Unfortunately, it is difficult to distinguish the signatures
that are a consequence of the dysfunction from the signa-
tures that cause the dysfunction.
A further complication is that the activity of the factors
that influence gene expression is difficult to observe
directly. For example, consider the simplest case of a sin-
gle transcription factor that regulates the expression of
one target gene. In this case, the activity of the transcrip-
tion factor may be governed by its past history of mRNA
expression, possible splice variants, protein modification,
binding with other factors, and where the transcription
factor is localized in the cell. In this case, the most direct
measure of the activity of the transcription factor is the
expression of the target gene itself. However, when multi-
ple genes are coordinately regulated by multiple regula-
tors, analyzing these cause and effect relationships
becomes more difficult.
One source of information relating transcription fac-
tors to their target genes is the transcription factor-DNA
binding information in databases such as TRANSFAC
and MsigDB [1,2]. However, knowing transcription fac-
tor-DNA binding relationships alone does not identify
which regulatory activities are relevant for a specific dis-
ease or tissue under study [3,4]. This limitation can be
partially overcome if gene expression data are integrated
with transcription factor-DNA binding information to
identify which transcriptional activities better explain the
observed expression variation.
Regulatory Networks-Bayesian (RegNetB)
In this work, we have developed and tested a tool called
Regulatory Networks-Bayesian, or RegNetB, to carry out
this integration of gene expression data and transcription
factor-DNA binding information. RegNetB uses a simplified
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layer of this network represents the group of unobserved
regulators (transcription factor activities) and the bottom
layer represents observed genes (mRNA expression values).
This regulatory bipartite network model has been used
elsewhere to represent transcriptional regulatory networks
by adopting a linear mixing model [5-8]. Other methods
such as NIR, CRL and ARACNE also attempt to identify
transcription factors-genes associations [9-11], however
these methods make a number of simplifying assumptions
that limit their applicability. In all cases, the activities of the
transcription factors is assumed to be proportional to the
expression level of the transcription factor–an assumption
that ignores the possible post translational regulation of
transcription factor activity. Furthermore, in the case of
NIR, linear modeling is used for this identification even
though transcriptional regulatory relationships could be
more complex. CRL and ARACNE adopt a mutual infor-
mation based approach to account for non-linearities.
However, the mutual information approach used in CRL
and ARACNE is limited to pairwise interactions and as
such would miss higher order phenomena. TF-Finder is
another method recently proposed that uses correlation
and linear combination maximization to propose a list of
potential transcription factors associated with the biological
processes described by the expression data used [12]. Here
we extend these models to account for both linear and non-
linear influences from a variable number of unobserved
regulators using a full Bayesian approach [13-15].
A common criticism when using Bayesian networks on
gene expression data is that loops are not permitted in a
Bayesian network structure. Nevertheless, because we are
not adopting a model where the activity of a transcription
factors is equivalent to its gene expression data, we can
represent the activity of transcription factor “A” (in the
top layer) regulating the expression of gene “A” (bottom
layer) without posing a violation on the Bayesian net-
works loops limitation. In other words, in our model, the
activity of transcription factor “A” and the expression of
gene “A” represent two different variables. This same
rationale applies to other structures like FFL (Feed For-
ward Loops)[16] that might be challenging to work with
a traditional Bayesian networks analysis.
RegNetB is tested using gene expression data from a
prostate cancer study carried out elsewhere [17,18].
Despite the high incidence and mortality rate, the mole-
cular mechanisms underlying the oncogenesis and pro-
gression of prostate cancer are still unclear. Significant
research has been dedicated to identifying prognostic
markers, however less research has focused on identifying
the regulatory mechanism that drives the disease [19].
By identifying a group of the most relevant regulatory
relationships, RegNetB is able to identify which
regulators are most likely responsible for the expression
variations in the prostate cancer study evaluated here. In
the next sections we describe the data processing and
results obtained after RegNetB analysis.
Methods
In the following section, we will describe the RegNetB
algorithm and the data preprocessing used in our test
cases.
RegNetB algorithm
The transcription factor-gene network presented here is
modeled as a Bayesian network by RegNetB. Regulators in
this network are modeled as hidden variables and the
observed variables (genes) are modeled using a multino-
mial model with Dirichlet priors as described elsewhere
[13-15] and in the supplemental material Additional file 1:
BDE_scoring_metric.doc. Below we provide a summary of
the scoring process.
For a typical Bayesian network scoring problem, a com-
plete discrete data set describing the variables included in
the network of interest is available. However, in this case
the transcription factors are not observed. To fill in the
activity levels for the regulators, a Gibbs sampler is used
to sample over the space unobserved regulators [20-23].
Gibb’s sampling and network scoring were carried out
using PEBL, a python library developed in our research
group [24]. PEBL estimates the probability of a discre-
tized dataset given a specific network using a Bayesian
Dirichlet equivalent metric described elsewhere [13]. The
source code of PEBL can be freely downloaded from
(http://code.google.com/p/pebl-project/).
Two scoring steps are performed by RegNetB to eval-
uate the relative strength of each connection in the tran-
scription factor-gene network. First, sample states of the
unobserved transcription factors are taken using a Gibbs
sampler. The sample states are taken after a burn in of
10 iterations. The second scoring step uses these sample
states to rescore the whole network when each tran-
scription factor-gene edge is removed and then re-
added. The relative importance of the edge can then be
interpreted as the change in the average score of the
network when the edge is removed versus present.
Source code for this scoring procedure is provided in
the additional file 2: RNB_scoring.py.
To generate the final list of regulators and genes of
interest in our study, we first ranked all the connections
based on the scores estimated by RegNetB. After nor-
malizing all the connection scores, a graphical analysis
was used to identify thresholds that differentiate a group
of relatively stronger connections from the rest based on
their scores. A list of all the genes and regulators was
generated from this set of connections.
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A global human transcription factor-gene network was
created using the Molecular Signatures Database
(MsigDB) [2]. The source of the “C3: Motif Gene Set”
information in this database, the collection we used to
create the global human transcription network, is
described elsewhere [25]. Briefly, the transcription factor
binding sites were predicted using promoter sequence
analysis, gene set enrichment analysis (GSEA), and com-
parative genomic analysis. After collecting these tran-
scription factor binding sites and the genes associated
with them, the gene names were mapped to their official
Entrez gene symbols. Only those genes mapping to
unique official gene symbols were included. Similarly,
some binding sites mapped to known transcription fac-
tors (regulators) names documented in TRANSFAC
while others were only described as the sequence of the
promoter itself. Regulatory sequences not mapping to
any known regulator were listed as UK (unknown) fol-
lowed by an integer.
Gene expression data
We used RegNetB to analyze 146 gene expression pro-
files from prostate tissue samples described elsewhere
[17,18] and available online on GEO as GDS2545. This
set of expression profiles includes 18 profiles from nor-
mal prostate tissues, 63 profiles from normal prostate tis-
sues adjacent to localized tumor, and 65 profiles from
primary prostate cancer tumors. The 146 gene expression
profiles were pre-processed using the web-based gene-
chip analysis system (WGAS) described elsewhere [26,27]
for data normalization and mapping of probe sets ID to
official gene symbols.
Next we filtered the gene list to only include genes that
could be meaningfully analyzed. The genes passing the
filter must: (1) exhibit differential expression across the
samples; (2) be present in the global human transcription
network; and (3) not have more than 10 regulators as
parents in the global human transcription network. The
first criterion was satisfied by selecting the top 500 genes
with the largest variation as measured by the magnitude
of the standard deviation of the expression values across
samples. The second and third criteria were then applied
to this list of 500 genes to identify genes in the network
with 10 or fewer regulators. We note that while it is pos-
sible that a gene with more than 10 regulators could
mechanistically participate in a strong regulatory rela-
tionship, this relationship will not be identifiable with a
small dataset in a multinomial model such as we are
using here. In a multinomial model, the number of para-
meters increases exponentially with the number of regu-
lators, making any relationship in a highly connected
gene weak. As such, by eliminating genes with more than
10 regulators we are eliminating genes that are unlikely
to score well.
Data discretization
The scoring metric used by RegNetB requires that the
data be discretized. The data for this study were binned
into three states describing a high, medium and low
expression level for the variables. The bin sizes were
evenly distributed across samples for each variable gener-
ating a discretized data set in which variables have their
top 1/3 of the data entries based on expression as “high”,
the bottom 1/3 of the entries as “low” and the remainder
1 / 3o ft h ee n t r i e sa s“medium”. This binning strategy (3
bins and evenly distributed) has been used elsewhere and
has been shown empirically to be robust in capturing
relevant details of the systems under study [11,28-31]. In
addition to following these strategies that are becoming a
standard in the systems biology community, there is a
strong computational incentive to keep the number of
discretization bins as small as possible. This incentive
arises because RegNetB uses a Gibbs sampling approach
to explore the possible configurations of the unobserved
regulators. As the number of bins increases, the size of
the search space increases exponentially. For example,
for a dataset with 100 observations and two unobserved
regulators, the configuration space of the unobserved
regulators is 3
100*2 ~1 0
95 for a 3 bin discretization, and
4
100*2 ~1 0
125 for a 4 bin discretization–an increase by a
factor of 10
30!
Results and Discussion
Global human transcription factor-gene network
The final global human transcription factor-gene bipartite
network generated from the MsigDB consists of 12,015
gene symbols and 391 regulators with a total of 134,573
regulator-gene associations. From these 391 regulators or
regulatory regions, 216 were associated with known tran-
scription factors names. The remaining 175 regulators
(UK1 to UK175) consisted of 60 known regulatory
sequences documented in TRANSFAC and 115 regulatory
sequences found and documented elsewhere [25]. This
global bipartite human transcription network is included
in the supplemental material additional file 3: global_-
human_transcription_net.xlsx. After filtering, we compiled
a final list of 253 genes and 292 regulators interconnected
in a bipartite network with 1,266 connections.
Strongest connections identified by RegNetB
Figure 1(A) shows the score distribution of transcription
factor-gene connections. Based on this distribution, we
selected the connections that ranked at the top area of
the curve illustrated in the Figure 1(A). This group of
regulatory connections shows a clear similarity in terms
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regulatory connections were collected, all with a score
>0.993, and are listed in the supplemental material addi-
tional file 4: top_regulatory_assoc.xls. Figure 1(B) shows
the top 10 connections from this list.
We evaluated the probability that a regulatory associa-
tion was picked within the top best 10, 50, 100 and 250
based on score when random values were assigned to the
regulator’s activities instead of the suggested sampling
from the expression data used by RegNetB (no signal).
This random-value test was run 5000 times. Estimation
of p-values < 0.05 supported that the selection of all the
top 10, 50 and 100 edges by RegNetB was not by a ran-
dom event. For the best top 250 edges, 70% of the edges
showed p-values < 0.05 supporting their selection from a
non-random event. In addition, after three independent
runs of RegNetB on the same dataset/initial network,
more than 95% of the top 250 associations based on
s c o r ew e r ec o n s i s t e n t l yp r e d i cted in the three runs, with
most of the 5% inconsistencies ranking in positions
225-275 (borderline).
After analysis of the posterior distribution of the net-
works scores, the top 218 networks based on score
showed statistically to be different (better) than the rest.
For this analysis, we compared each “edge” disconnection
score to the initial network score. This score comparison
tested which connections, compared to all others, showed
to negatively affect more the score of the initial network
when they were disconnected (more relevant edges). The
top 218 edges based on score showed a p-value < 0.05.
This is consistent with the results explained in the pre-
vious paragraph.
We also noticed that not all connections associated
with a regulator included in the top 250 strongest
connections list were part of the group of top connec-
tions. This relative strength distribution implies that
some regulatory connections associated with a specific
r e g u l a t o rp l a yam o r er e l e v a n tr e g u l a t o r yf u n c t i o nt h a n
the others.
PAX4 regulatory role
Regulation of RLN1 by PAX4 ranked top on the list of
strong connections in Figure 1(B). Similarly, the regula-
tion of RLN2 by PAX4 also ranked well (fifth position).
RLN1 and RLN2 have been associated with prostate
cancer in other studies [32]. The regulator PAX4 has
been identified as a tumor suppressor in melanoma stu-
dies [33], however has not been associated with prostate
cancer [34].
To further evaluate the RegNetB prediction of PAX4’s
influence on RLN1 and RLN2, we examined the expres-
sion levels of the target genes and any other regulator(s)
associated with the genes. As shown in Figure 2(A), the
expression patterns of RLN1 and RLN2 share a strong
similarity in terms of regulation not only by the topolo-
gical model but also by the coordinated linear pattern
observed in the data. This observation supports the pre-
diction that PAX4 is a common factor responsible for
changes in the expression of RLN1 and RLN2.
ACPP (PAP) regulation
Another connection observed in the strong connection
list shown in Figure 1(B) was the regulation of ACPP by
JUN. ACPP or PAP (Prostatic Acid Phosphatase) is a
known prostate cancer marker used to monitor tumor
progression and/or patients improvement [35]. RegNetB
suggested that the main regulatory activity associated
with this gene is best described by the regulators JUN,
Figure 1 Connections ranked by score. (A) Relative score distribution for the regulatory connections kept after RegNetB analysis. The
shadowed region shows the top 250 connections based on score.. (B) Top 10 connections predicted by RegNetB.
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associated with different types of cancer including pros-
tate cancer tumor progression [36,37]. In the case of
BACH1 and BACH2, even though there are some asso-
ciations with breast cancer and leukemia[38,39], we
found no links with prostate tumor progression.
MAZ and TAF8 co-regulation
To further explore RegNetB’s results, we examined sets
of two or more genes that shared the same group of
regulators within the selected list of 250 regulatory con-
nections. We found two genes, PGC and GDF15 that
are both co-regulated by TAF8 and MAZ. Both PGC
and GDF15 have been associated with prostate cancer
and have been documented as potential biomarkers
[40-42]. Figure 2(B) shows coordinated patterns between
these genes but not in a linear manner. Interestingly,
MAZ and TAF8 have been associated with other types
of cancer [43-45], but we found no reports associating
MAZ and TAF8 with prostate cancer.
Conclusions
These results suggest that RegNetB is able to identify
physiologically relevant regulatory protein-gene relation-
ships based on gene expression data. Many of the target
genes identified by RegNetB have been implicated in
prostate cancer progression, but the relevant regulation is
largely new. In particular, RegNetB identified the regula-
t o r sP A X 4 ,B A C H 1 ,B A C H 2 ,M A Za n dT A F 8a sp l a y i n g
a central role in this prostate cancer gene expression data
set. Most of the significant associations predicted in this
work are currently being experimentally evaluated.
The method used by RegNetB can be directly applied
to any gene expression dataset, as long as a transcrip-
tional regulatory network is known for the organism. We
acknowledge that gene regulations are hardly a one-step
process and other genes beside the ones predicted by
RegNetB will change as well because they were not part
of the initial network or because of others regulatory
events not captured by the integrated data used. What
we intended in this work was to present a systematic pro-
cedure to filter and predict a set of regulatory associa-
tions that more likely explain most of the changes in
expression. By identifying such explanatory regulatory
protien-gene relationships, RegNetB allows a researcher
to look beyond changes in gene expression, and start to
identify possible causes for that change in expression.
Additional material
Additional file 1: Bayesian Dirichlet metric. This document includes
more details about the BD scoring metric used in this work as well as an
explanation of the Gibbs sampler integrated for the scoring in the
presence of hidden variables or missing entries in general.
Additional file 2: RegNetB scoring script. This file contain the script
used to sample the hidden variables and score all the networks resulting
from each edges disconnections to estimate each edge relative strength.
Additional file 3: Global human bipartite transcription network. This
file contains all the regulatory associations gathered from the MsigDB
database and a map for the regulators identified as “UK” (unknown) with
their respective promoter regulatory sequence.
Additional file 4: Top 250 regulatory associations found in this
work. This file contains a table with the list of the top-ranked regulatory
associations based on score found by RegNetB.
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Figure 2 Top scoring regulatory relationships and discretized data patterns. Each grid in (A) and (B) shows the nine possible state
combinations in which each pair of variables is observed in the discretized expression data. In the regulatory networks, the dotted ovals
represent regulators while the solid ovals represent target genes. (A) RLN1 and RLN2 expression and regulatory network. Note that RLN1 and
RLN2 show a nearly linear co-expression pattern. (B) PGC and GDF15 expression and regulatory network. The expression pattern of PGC relative
to GDF15 does not show a linear pattern, but still scores well in the multinomial model used by RegNetB.
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